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Abstract A correlation has been established between the
absorbed fraction of training-set molecules after oral
administration in humans and the Quantum Mechanical
Polar Surface Area (QMPSA). This correlation holds for
the QMPSA calculated with structures where carboxyl
groups are deprotonated. The correlation of the absorbed
fraction and the QMPSA calculated on the neutral gas
phase optimized structures is much less pronounced. This
suggests that the absorption process is mainly determined
by polar interactions of the drug molecules in water solu-
tion. Rules are given to derive the optimal polar/apolar
ranges of the electrostatic potential.
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Introduction
The polar surface area (PSA) has been used successfully to
predict the absorption of drugs [1]. The polar surface area
is deﬁned as the combined surface area belonging to oxy-
gen and nitrogen atoms and hydrogen atoms bound to these
electronegative atoms. Methods to improve the correlation
between polar surface area and absorption of drugs evolved
in the years thereafter. The Dynamic Polar Surface Area
(DPSA) is derived from Boltzmann-averaged ensembles of
low energy molecular conformations [2]. The Topological
Polar Surface Area (TPSA) is fragment-based methodology
which derived standardized contributions to the molecular
polar surface area from functional groups and atom types
[3]. Various protocols have been reported to calculate the
PSA on different surfaces (van der Waals [1], Connolly, or
solvent accessible surface [4].
The term polar surface area suggests that the absorption
is related to the physical interaction of surfaces through
their electrostatic potential. In this work we present a study
of the correlation of the quantum mechanical electrostatic
potential and the absorption of drugs in humans. In the
original work by Palm et al. [1] the surface was constructed
by intersecting atomic spheres deﬁned by van der Waals
radii. In line with our quantum mechanical approach in this
work the electrostatic potential will be calculated on a
surface with constant electron density or isodensity surface.
The algorithm by Palm et al. was incorporated to our
MOLDEN molecular modeling package [5] for compari-
son. Choices have to be made about which value of the
electron density the isodensity surface is most suited to
calculate the electrostatic potential.
Secondly, a range of the electrostatic potential has to be
deﬁned as polar and a complementary range as apolar. The
sum of all parts of the isodensity surface with an electro-
static potential in the polar range is then deﬁned as the
polar surface area.
Methods
The structures of the training-set molecules were kindly
provided by Popelier et al. [6], the authors of a paper on the
quantum chemical calculation of the topological polar
surface area. For a detailed description on how these
structures were derived, we refer to this paper [6].
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calculated and used in this work. Low-energy conforma-
tions for each molecule in the training-set were obtained
from Monte Carlo multiple minimum (MCMM) searching,
using the OPLS-AA force ﬁeld.
The MCMM [7]/OPLS-AA [8] geometries were used as
the starting point for the quantum mechanical geometry
optimizations at the B3LYP/6–31G**//B3LYP/6–31G**
level of theory [9] using the Jaguar program [10].
A validation set of compounds with absorbance data in
humans, was obtained from J.Kelder et al. [11]. The vali-
dation set will be used to determine whether the optimized
ranges of the electrostatic potential for polar and apolar
surface are also valid for an independent set of molecules.
Single-point energy calculations were performed with
the optimized geometries by the program Gamess-US [12]
at the B3LYP/6–31G** level, to generate the wave func-
tion ﬁles required for the calculations of the electron den-
sity and electrostatic potential on a three dimensional grid
or cube ﬁle with the Molden (version 4.7) program [5].
T h e s ec u b eﬁ l e sa r es u b s e q u e ntly used to map the electro-
static potential onto an isodensity surface with the Molden
program.Theisodensitysurfaceisrepresentedasacollectionof
triangles, calculated with the marching cube algorithm imple-
mented in Molden. The electrostatic potential of the vertices of
each triangle is interpolated from the potential of the eight grid
points of the cube marching [13] over the three dimensional
grid. The polar surface area is calculated as the sum of the
triangular areas with the potential in the polar range. When not
all vertices are in the polar range the triangles are subdivided
into four smaller triangles. This process is repeated until all
vertices are either in the polar range or all in the apolar range.
Sigmoidal ﬁts between the QMPSA and the fraction
absorbed in humans (FA) were performed using the four
parameter Weibull equation:
FA ¼ a   b exp  c QMPSAd 
Where a, b, c and d are parameters to be ﬁtted.
Results and discussion
Isodensity surfaces
Varyingthevalueoftheelectrondensityoftheisodensitywe
establishedthatavalueof0.0005electrons/bohr
3wouldgive
a surface most compatible with the van der waals surface
used by Palm et al. [1]. Table 1 shows the total surface area
for the training-set molecules with both methods. The root
mean square deviation is 9 A ˚ 2 which is around 3%.
The electron density that best matches the van der Waals
surface is relatively low. Quantum mechanical methods
optimize the electron density with respect to the energy.
An artifact of these methods is that the contribution to
the electron density by energy rich inner shell electrons/
orbitals is optimized at the expense of that of the outer shell
and valence electrons/orbitals, when not using a complete
basis-set [14]. In the same spirit it can be argued that the
electron density at locations that contribute higher to the
energy is optimized at the expense of quality of the elec-
tron density at locations that contribute less to the energy.
In order to avoid/evaluate this complication the Quantum
Mechanical Polar Surface Area (QMPSA) will also be
evaluated on isodensity surfaces with a higher electron
density.
Polar and apolar range of electrostatic potential
Experimenting with upper and lower bound of the elec-
trostatic potential deﬁned as apolar, the following obser-
vations were made. Choosing the upper bound of the apolar
electrostatic potential (ESPapolar,high) too low results in
hydrogens connected to phenyl rings to contribute to polar
surface with positive electrostatic potential (see Fig. 1 and
Fig. 2). Conversely, choosing the lower bound of the
apolar potential (ESPapolar,low) too high, results in the
electron density above and under the phenyl rings to con-
tribute to the polar surface area with negative electrostatic
potential. Phenyl rings constitute a major part of the
isodensity surface, and since these atoms do not contribute
Table 1 Comparison between the quantum mechanical total surface
area of the isodensity surface at 0.0005 electrons/bohr3 and the
topological surface area by Palm et al. [1]
Drug Quantum mechanical
surface area (A ˚ 2)
Topological surface
area (A ˚ 2)
Metoprolol 382 385
Nordiazepam 312 311
Diazepam 329 332
Oxprenolol 354 372
Phenazone 253 248
Oxazepam 320 317
Alprenolol 354 360
Practolol 369 365
Pindolol 342 335
Ciproﬂoxacin 364 364
Metolazone 383 385
Tranexamic 218 213
Atenolol 367 364
Sulpiride 407 407
Mannitol 224 216
Foscarnet 143 130
Sulfasalazine 432 415
Olsalazine 336 315
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ESPapolar,high were chosen such that the phenyl rings do not
contribute to the Quantum Mechanical Polar Surface Area
(QMPSA).
Correlation between QMPSA and the absorbed fraction
of training-set molecules
Table 2 shows the calculated QMPSA and the absorbed
fraction (FA) of traning-set molecules [1], on the isodensity
surfaces with density values 0.01 and 0.0005 e/Bohr
3.
Upper and lower bound of the polar electrostatic potential
were chosen according to the rules set out in the previous
section and were optimized to yield the highest correlation
coefﬁcient between the QMPSA and the absorbed fraction
of the training-set molecules.
The correlation between the absorbed fraction of the
training-set molecules and the QMPSA is relatively low
compared to the reported sigmoidal correlation between
topological polar surface area and the absorbed fraction.
Correlation coefﬁcients for a linear ﬁt are 0.68 and 0.30 for
density values 0.01 and 0.0005 e/bohr
3 respectively. Cor-
relation coefﬁcients for a sigmoidal ﬁt are slightly better:
0.74 and 0.36 for density values 0.01 and 0.0005 e/bohr
3
respectively.
A graphical inspection of the QMPSA revealed the
reason for the often relatively low values of the QMPSA
with respect to the topological polar surface area. Figure 3
shows the electrostatic potential mapped onto the isoden-
sity surface for the training-set molecule sulfasalazine.
Figure 4 shows the structural formula of sulfasalazine.
QMPSA surface areas are marked with the red and blue
colors. Red and blue represent polar surface areas with
respectively positive and negative electrostatic potentials.
The hydrogen of hydroxyl group attached to the phenyl
ring points towards the oxygen of the carboxyl group in the
optimized sulfasalazine structure. The positive electrostatic
potential exerted by the hydroxyl hydrogen cancels out the
negative electrostatic potential exerted by the carboxyl
oxygen. The resultant potential has a low absolute value
and is therefore classiﬁed as an apolar potential.
In general optimized structures in the gas phase will
tend to have their electronegative atoms (O, N) oriented
towards electropositive counterparts (H), whereas mole-
cules in a polar solvent such as water will tend to have both
their electronegative and electropositive atoms accessible
for interaction with the solvent.
The absorbed fraction pertains to the fraction of mole-
cules in solution, absorbed into the apolar membranes of
the gut. Gas phase optimized structures are therefore best
suited to represent the absorbed state of the training-set
molecules. The water solved state of the molecules can
probably best be represented by taking into account the
neutral species and the deprotonated species, with their
electronegative atoms accessible to the solvent.
Inﬂuence of the protonation state of acids
The carboxyl group of the molecules in our training-set can
lose their proton depending on the pH with respect to the
acid’s pKa. In our training-set three molecules contain a
carboxyl group: ciproﬂoxacin, sulfasalazine and olsalazine.
The latter two have pKa’s such that the they are dissociated
at the pH of the gut (pH = 5.7–6.6 [15]). Ciproﬂoxacin
however has a pKa that falls in the pH range of the gut
(pKa = 6.09 [16]). We assume therefore that half of the
ciproﬂoxacin molecules are dissociated and the other half
are not.
Fig. 1 Quantum mechanical polar surface area (red and blue) for the
training-set molecule diazepam when choosing the apolar electro-
static potential range incorrectly (ESPapolar,high 0.01, ESPapolar,low
-0.028)
Fig. 2 Structural formula diazepam
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calculated on the deprotonated species. The QMPSA of
ions is dominated by the charge center and is therefore
much larger than their neutral counterparts. For sulfasala-
zine for example the QMPSA for the anion is 198.7 A ˚ 2
versus 56.0 A ˚ 2 for the neutral species. In aqueous solution
however, counter ions are always present at some distance.
Table 2 QMPSA calculated at
different density values versus
absorbed fraction of the
gasphase optimized training-set
molecules
Drug QMPSA (A ˚ 2) QMPSA (A ˚ 2) Absorbed Fraction
Density 0.01 e/bohr
3
ESPapolar,low -0.028
ESPapolar,high 0.115
Density 0.0005 e/bohr
3
ESPapolar,low -0.025
ESPapolar,high 0.043
Metoprolol 20.8 31.1 102
Nordiazepam 18.4 35.0 99
Diazepam 15.2 29.6 97
Oxprenolol 19.5 27.1 97
Phenazone 13.0 33.7 97
Oxazepam 26.2 48.0 97
Alprenolol 15.3 14.3 96
Practolol 25.7 37.6 95
Pindolol 17.6 43.4 92
Ciproﬂoxacin 34.3 57.5 69
Metolazone 46.6 97.2 64
Tranexamic 20.3 28.9 55
Atenolol 28.2 39.7 54
Sulpiride 45.3 80.8 36
Mannitol 40.2 48.6 26
Foscarnet 35.1 42.4 17
Sulfasalazine 37.7 49.8 12
Olsalazine 27.7 30.2 2.3
Fig. 3 Quantum mechanical polar surface area (red and blue) for the
training-set molecule sulfasalazine
Fig. 4 Structural formula sulfasalazine
Fig. 5 Quantum mechanical polar surface area (red and blue) for the
test-set molecule sulfasalazine with carboxyl group deprotonated
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approximate distance for the counter ion to the central
carbon of the carboxyl group (2.281 A ˚). Placing a positive
point charge at this distance, the QMPSA for the anion-
point charge complex was calculated. The QMPSA cal-
culated in this way should be considered to be a lower
bound for the QMPSA of the dissociated acid, since the
distance of the counter charge will be larger in aqueous
solution. The QMPSA for ciproﬂoxacin, sulfasalazine and
olsalazine are 48.6, 59.8 and 62.8 A ˚ 2 respectively versus
34.4, 37.7 and 27.7 A ˚ 2 respectively in the neutral species.
For ciproﬂoxacin we take the average of the anion and the
neutral species: 41.8 A ˚ 2.
Figure 5 shows the electrostatic potential mapped onto
the isodensity surface for the deprotonated training-set
molecule sulfasalazine.
Table 3 shows the calculated QMPSA and the absorbed
fraction (FA) of training-set molecules with carboxyl groups
deprotonated, on the isodensity surfaces with density values
0.01 and 0.0005 e/bohr
3. The correlation between the absor-
bed fraction of the training-set molecules and the QMPSA is
signiﬁcantly better compared to that of the neutral gas phase
optimized structures.
Correlation coefﬁcients for a linear ﬁt are 0.87 and 0.84
for density values 0.01 and 0.0005 e/bohr
3 respectively.
Correlation coefﬁcients for a sigmoidal ﬁt are also better:
Table 3 QMPSA calculated at
different density values versus
absorbed fraction of the
training-set molecules with
deprotonated carboxyl groups
Drug QMPSA (A ˚ 2) Absorbed fraction
Density 0.01 e/bohr
3
ESPapolar,low -0.028
ESPapolar,high 0.115
Density 0.0005 e/bohr
3
ESPapolar,low -0.025
ESPapolar,high 0.043
Metoprolol 20.8 31.1 102
Nordiazepam 18.4 35.0 99
Diazepam 15.2 29.6 97
Oxprenolol 19.8 36.9 97
Phenazone 13.0 33.7 97
Oxazepam 26.2 48.0 97
Alprenolol 17.1 20.8 96
Practolol 29.5 45.5 95
Pindolol 21.3 43.4 92
Ciproﬂoxacin 41.8 83.8 69
Metolazone 46.6 97.2 64
Tranexamic 25.2 44.8 55
Atenolol 32.4 49.9 54
Sulpiride 45.3 80.8 36
Mannitol 57.1 78.5 26
Foscarnet 43.0 62.9 17
Sulfasalazine 59.8 118.3 12
Olsalazine 62.8 103.5 2.3
Fig. 6 Linear correlation between the absorbed fraction of training-
set molecules with deprotonated carboxyl groups and the QMPSA
Fig. 7 correlation between the absorbed fraction of training-set
molecules with deprotonated carboxyl groups and the QMPSA
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3
respectively.
Figure 6 and Fig. 7 show respectively the linear and
sigmoidal correlation between the absorbed fraction of
training-set molecules with carboxyl groups deprotonated,
and the QMPSA calculated on the isodensity surface with
density value 0.01 e/bohr
3.
Correlation between QMPSA and the absorbed fraction
of validation-set molecules
Table 4 shows the calculated QMPSA and the absorbed
fraction (FA) of validation-set molecules with deprotonated
carboxyl groups, on the isodensity surfaces with density
values 0.01 and 0.0005 e/bohr
3. Correlation coefﬁcients for
a linear ﬁt are 0.96 and 0.95 for density values 0.01 and
0.0005 e/bohr
3 respectively. Correlation coefﬁcients for a
sigmoidal ﬁt are slightly better and worse: 0.98 and 0.87 for
density values 0.01 and 0.0005 e/bohr
3 respectively.
Figure 8 and Fig. 9 show respectively the linear and
sigmoidal correlation between the absorbed fraction of
combined validation- and training-set molecules and the
QMPSA calculated on the isodensity surface with density
value 0.01 e/bohr
3, with correlation coefﬁcients of 0.86
and 0.92 respectively. The combined set shows an equally
good sigmoidal correlation compared to the training-
set alone (0.92 versus 0.92). Although the isodensity
Table 4 QMPSA calculated at
different density values versus
absorbed fraction of the
validation-set molecules
Drug QMPSA (A ˚ 2) QMPSA (A ˚ 2) Absorbed fraction
Density 0.01 e/bohr
3
ESPapolar, low -0.028
ESPapolar, high 0.115
Density 0.0005 e/bohr
3
ESPapolar, low -0.025
ESPapolar, high 0.043
Caffeine 27.0 40.0 100
Salicylic acid 30.7 54.4 100
Norgestrel 22.1 37.9 100
Felodipine 30.5 38.0 100
Tiacrilast 30.9 42.3 99
Theophylline 32.2 51.9 98
Testosterone 21.9 40.5 98
Verapamil 33.3 58.3 95
Warfarine 28.2 54.7 93
Diltiazem 28.2 43.6 92
Propranolol 16.6 21.6 90
Hydrocortisone 42.0 62.1 89
Cimetidine 37.1 78.9 84
Terbutaline 32.7 53.4 73
Ceftriaxone 93.1 181.1 1
Aztreonam 98.8 155.9 0
Fig. 8 Linear correlation between the absorbed fraction of train-
ing ? validation-set molecules and the QMPSA
Fig. 9 Sigmoidal correlation between the absorbed fraction of
training ? validation-set molecules and the QMPSA. Sigmoidal ﬁt
parameters: a = 94.05, b = 98.47, c = 3327398.1, d =- 4.0328
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3 best represents the van der
Waals surfaces used in the original work of Palm et al., for
the calculation of the QMPSA the use of 0.01 e/bohr
3
isodensity surfaces consistently give better ﬁts and are
therefore recommended together with ESPapolar,low of
-0.028 and ESPapolar,high of 0.115.
Relation between gas phase and solvent optimised
structures
To assess the inﬂuence of gas phase versus solvent opti-
mized structures on the correlation between QMPSA and
absorbed fraction in humans, the training set of molecules
was optimized with an explicit water for each hydrogen
bond donor using the Polarizable Continuum solvent
Model (PCM) [17]. The 4–31G* basis set was used at the
Hartree–Fock level of theory. After optimization the
explicit waters are removed and the QMPSA is calculated
at the B3LYP/6–31G** level of theory at the PCM opti-
mized geometries.
Table 5 shows the results. Comparing with the gas phase
approach, the QMPSA changes are small (RMSD 1.73 A ˚ 2).
Correlation coefﬁcients for a linear and sigmoidal ﬁt
are 0.86 and 0.91 respectively for isodensity values
0.01 e/bohr
3 (versus 0.87 and 0.92 respectively for gas
phase approach).
The correlation between QMPSA and absorbed fraction
in humans is expected to improve when using ensembles of
low energy molecular conformations as in the Dynamic
Polar Surface Area method [2], but was not further
investigated.
Figure 10 mannitol with six explicit waters optimized
with the PCM solvent model at the Hartree–Fock level of
theory with the 4–31G* basis set.
QMPSA basis set and level of theory dependency
Table 6 shows that the QMPSA is in general weakly
dependent on the used basis set. The root mean square
deviation for nordiazepam, tranexamic and sulfasalazine is
0.14, 0.69 and 3.96 respectively (1, 2 and 5%) over the
employed basis sets. The compounds were chosen to rep-
resent the apolar, medium polar to polar spectrum. The
RMSD increases with the polarity of the compounds.
Going from the Hartree–Fock level of theory to B3LYP,
the QMPSA decreases by 10%(see Table 5 and Table 6
basis set 6–31G**). This is not surprising since the Har-
tree–Fock method is known to overestimate the polarity
[18].
Table 5 QMPSA calculated at density value 0.01 e/bohr
3 versus
absorbed fraction of the test-set molecules with deprotonated car-
boxyl groups optimized with the PCM model at the Hartree–Fock
level of theory with the 4–31G* basis-set
Drug QMPSA (A ˚ 2) Absorbed fraction
Density 0.01 e/bohr
3
ESPapolar,low -0.028
ESPapolar,high 0.115
Metoprolol 20.9 102
Nordiazepam 18.4 99
Diazepam 15.7 97
Oxprenolol 23.2 97
Phenazone 14.0 97
Oxazepam 27.3 97
Alprenolol 14.7 96
Practolol 28.4 95
Pindolol 20.7 92
Ciproﬂoxacin 48.6 69
Metolazone 47.3 64
Tranexamic 25.2 55
Atenolol 31.5 54
Sulpiride 46.0 36
Mannitol 55.7 26
Foscarnet 39.6 17
Sulfasalazine 59.8 12
Olsalazine 62.8 2.3
Fig. 10 PCM/4–31G* optimized structure of mannitol with six
explicit water molecules
Table 6 The QMPSA calculated with different basis sets at the
Hartree–Fock level of theory with the PCM solvent model optimized
geometries
QMPSA (A ˚ 2)
Density 0.01 e/bohr
3
ESPapolar,low -0.028
ESPapolar,high 0.115
Drug/basis set 3–21G 4–31G 6–31G**
Nordiazepam 20.7 20.7 21.0
Tranexamic 29.9 29.8 28.4
Sulfasalazine 73.4 73.2 64.9
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A good correlation has been established between the
absorbed fraction of training-set molecules after oral
administration in humans and the Quantum Mechanical
Polar Surface Area (QMPSA). This correlation holds for
the QMPSA calculated with structures where the carboxyl
groups are deprotonated. The correlation of the absorbed
fraction and the QMPSA calculated on the gas phase
optimized structures is much less pronounced. This sug-
gests that the absorption process is mainly determined by
polar interactions of the molecules in water solution.
The QMPSA is weakly dependent on the used basis set
and drops 10% on going from Hartree–Fock to B3LYP.
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